Pages that link to "Q30762470"

The following pages link to Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study. (Q30762470):

Displaying 28 items.

• High frequency of Fredrickson's phenotypes IV and IIb in Brazilians infected by human immunodeficiency virus (Q24814179) (← links)
• When patients cannot take pills: antiretroviral drug formulations for managing adult HIV infection (Q26999410) (← links)
• Use of observational data in evaluating treatments: antiretroviral therapy and HIV. (Q30969932) (← links)
• Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 study (Q34032348) (← links)
• Coronary heart disease risk, dyslipidemia, and management in HIV-infected persons (Q36025409) (← links)
• Atherosclerotic cardiovascular disease risk in the HAART-treated HIV-1 population (Q36070094) (← links)
• Antiretroviral therapy in advanced HIV-1 infection (Q36120482) (← links)
• Treatment of dyslipidaemia in HIV-infected persons (Q36222023) (← links)
• Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics (Q36505229) (← links)
• Development of appropriate coronary heart disease risk prediction models in HIV-infected patients. (Q37111718) (← links)
• Mind the gap: difference between Framingham heart age and real age increases with age in HIV-positive individuals-a clinical cohort study (Q37256483) (← links)
• Coronary artery disease in patients with HIV infection (Q38352065) (← links)
• Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects (Q40488051) (← links)
• The influence of symptom experiences and attributions on adherence to highly active anti-retroviral therapy (HAART): a six-month prospective, follow-up study. (Q44604254) (← links)
• Rapid progression of atherosclerotic coronary artery disease in patients with human immunodeficiency virus infection (Q45435499) (← links)
• Impact of different low-dose ritonavir regimens on lipids, CD36, and adipophilin expression (Q46177989) (← links)
• Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone (Q46789882) (← links)
• Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen. (Q46792927) (← links)
• Ten-year predicted coronary heart disease risk in HIV-infected men and women (Q51107767) (← links)
• Cardiovascular risk assessment in persons with HIV infection in the developing world: comparing three risk equations in a cohort of HIV-infected Thais. (Q51596082) (← links)
• Collaborative care for the detection and management of depression among adults with hypertension in South Africa: study protocol for the PRIME-SA randomised controlled trial. (Q51736515) (← links)
• The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. (Q51943315) (← links)
• [Cardiovascular risk assessment and intervention in HIV-infected patients]. (Q52398757) (← links)
• Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study (Q56530639) (← links)
• Kommerzielle Systeme zur Genotypisierung von humanen Immundefizienzviren Typ 1: Vergleich von ViroSeq (Abbott) und TruGene (Bayer). Commercially available assays for genotyping of human immunodeficiency virus type 1: Comparison of ViroSeq (Abbott) an (Q57083225) (← links)
• Risk of coronary heart disease among HIV-infected patients: a multicenter study in Brazil (Q59033147) (← links)
• AIDS case reporting: do we still need it? (Q81750945) (← links)
• Cardiovascular adverse events during treatment with darunavir-based regimens in an Italian observational study (Q92696173) (← links)